EOI::implementing the presidents department of government efficiency cost efficiency initiative (march 19, 2025)::EOI
Ended Awarded Last action
- Contract number
- 75N91024F00023
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- -$71,170
Award facts
- Contract value 0% obligated
- $637,460.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$71,170 | |
| Terminate for Convenience | $0 | |
| Original award | $708,630 |
About this award
Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. and Federally Funded Research and Development Center (FFRDC) contractor, received a delivery order valued at $637,460 from the National Cancer Institute (NCI) with an award date of July 8, 2024 and an ultimate completion date of March 6, 2026. The contract is structured as a cost-plus-fixed-fee delivery order with no set-aside designation, indicating competitive award based on the contractor's demonstrated capabilities. The work will be performed at the Frederick National Laboratory for Cancer Research in Frederick, Maryland, where Leidos Biomedical Research Inc. maintains substantial biomedical research and facilities support operations.
This delivery order supports the National Cancer Institute's mission and contributes to the implementation of cost efficiency initiatives as indicated by the award description. Leidos Biomedical Research Inc. has established a strong track record with the NCI and National Institutes of Health through multiple cost-plus-fixed-fee delivery orders focused on diverse scientific domains including cancer research, gene therapy development, clinical trials, and advanced laboratory capabilities. The company's parent entity, Leidos Holdings, Inc., operates as a large prime federal contractor with extensive government relationships and a multi-billion dollar federal contract portfolio, providing the financial and operational stability required to support complex biomedical research initiatives.
Quick answers
Who was awarded contract 75N91024F00023?
75N91024F00023 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on July 8, 2024.
How much is contract 75N91024F00023 worth?
The government has obligated -$71,170 on 75N91024F00023. Its current value, with exercised options, is $637,460.
Is contract 75N91024F00023 an order under another contract?
Yes. 75N91024F00023 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91024F00023 competed?
The extent of competition for 75N91024F00023 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award